Zealand Pharma A/S

(NASDAQ:ZEAL)

Latest On Zealand Pharma A/S (ZEAL):

Date/Time Type Description Signal Details
2022-11-10 10:48 ESTNewsZealand Pharma reports nine-month resultsN/A
2022-10-05 01:47 ESTNewsZealand Pharma announces private placement of 4.5M new sharesN/A
2022-09-30 11:48 ESTNewsZealand says short bowel syndrome therapy reached main goal in Phase 3 trialN/A
2022-09-07 12:16 ESTNewsNovo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for ZegalogueN/A
2022-08-24 14:58 ESTNewsZealand Pharma appoints CFON/A
2022-08-09 15:58 ESTNewsZealand Pharma to delist U.S.-listed shares, consolidate trading to Nasdaq CopenhagenN/A
2022-06-21 20:38 ESTNewsZealand Pharma, Iktos team up to develop AI tech for peptide drug designN/A
2022-05-19 14:40 ESTNewsZealand Pharma stock soars 17% as dasiglucagon meets main goal in congenital hyperinsulinism study in infantsN/A
2022-05-12 10:06 ESTNewsZealand Pharma GAAP EPS of -DKK5.16 misses by $4.18, revenue of DKK15.07M beats by DKK5.59MN/A
2022-05-10 20:32 ESTNewsZealand Pharma, Oberland Capital amend financing contractN/A
2022-03-30 12:27 ESTNewsZealand Pharma stock rises 10% on restructuring plan, new CEON/A
2022-01-20 14:05 ESTNewsZealand Pharma completes enrollment in phase 3 glepaglutide study for short bowel syndromeN/A
2021-12-15 03:33 ESTNewsZealand Pharma inks 7-year, $200M financing deal with Oberland CapitalN/A
2021-11-22 16:24 ESTNewsZealand Pharma reports successful outcome of Phase 1b trial with dapiglutideN/A
2021-11-05 18:55 ESTNewsZealand Pharma and DEKA Research ink collaboration agreementN/A
2021-11-04 22:34 ESTNewsZealand Pharma gets dosing underway in Phase 1 ZP8396 obesity trialN/A
2021-10-12 18:17 ESTNewsWarning: ZEAL is at high risk of performing badlyN/A
2021-10-07 01:25 ESTNewsZEAL is at high risk of performing badlyN/A
2021-10-05 22:53 ESTNewsWarning: ZEAL has been downgraded to Very BearishN/A
2021-08-20 17:20 ESTNewsZealand Pharma raises share capital after employees exercise warrantsN/A
2021-08-19 20:23 ESTNewsDosing underway in Zealand Pharma's late-stage glepaglutide study in short bowel syndromeN/A
2021-07-22 15:33 ESTNewsBoehringer Ingelheim and Zealand Pharma get FDA fast track status for NASH treatmentN/A
2021-07-22 15:32 ESTNewsZealand Pharma increases share capital led by employee warrants exerciseN/A
2021-07-22 15:30 ESTNewsZealand Pharma starting share buyback program for employee incentives programN/A
2021-04-14 01:27 ESTNewsBoehringer Ingelheim, Zealand Pharma initiate mid-stage NASH and obesity studiesN/A
2021-03-23 16:53 ESTNewsZealand Pharma surges on news of FDA approval for dasiglucagon (updated)N/A
2021-03-22 20:17 ESTNewsZealand Pharma surges on news of FDA approval for dasiglucagonN/A
2021-03-20 09:01 ESTNewsSeeking Alpha Catalyst WatchN/A
2021-03-18 07:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $39.67 to $39.59.Neutral
2021-03-17 15:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $39.76 to $39.67.Neutral
2021-03-16 23:47 ESTFinancialsCompany financials have been released.Neutral
2021-03-16 23:47 ESTEarnings EstimateAn EPS average of -$0.98 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 23:47 ESTEarnings EstimateAn EPS average of -$0.99 is estimated for the quarter ending on March 31, 2021.Buy
2021-03-16 23:47 ESTAnalyst RatingThe Analyst Target Price has increased from $38.67 to $39.76.Buy
2021-03-13 05:48 ESTAnalyst RatingThe Analyst Target Price has increased from $38.48 to $38.67.Buy
2021-03-12 06:10 ESTAnalyst RatingThe Analyst Target Price has increased from $38.45 to $38.48.Buy
2021-03-12 06:10 ESTEarnings EstimateAn EPS average of -$3.20 is estimated for the 2022 year.Sell
2021-03-11 20:35 ESTNewsZealand Pharma misses on revenueN/A
2021-03-11 05:52 ESTAnalyst RatingThe Analyst Target Price has increased from $38.29 to $38.45.Buy
2021-03-10 06:27 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.55 to $38.29.Neutral
2021-03-09 05:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.67 to $38.55.Neutral
2021-03-06 02:07 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.94 to $38.67.Neutral
2021-03-05 17:41 ESTAnalyst RatingThe Analyst Target Price has increased from $38.6 to $38.94.Buy
2021-03-05 09:53 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.73 to $38.6.Neutral
2021-03-04 05:54 ESTAnalyst RatingThe Analyst Target Price has increased from $38.61 to $38.73.Buy
2021-03-03 09:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.74 to $38.61.Neutral
2021-03-02 17:42 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.97 to $38.74.Neutral
2021-02-27 05:49 ESTAnalyst RatingThe Analyst Target Price has decreased from $38.99 to $38.97.Neutral
2021-02-26 22:21 ESTAnalyst RatingThe Analyst Target Price has decreased from $39.42 to $38.99.Neutral
2021-02-26 06:05 ESTAnalyst RatingThe Analyst Target Price has increased from $39.36 to $39.42.Buy

About Zealand Pharma A/S (ZEAL):

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

ZEAL Quotes by TradingView

See Advanced Chart

General

  • Name Zealand Pharma A/S
  • Symbol ZEAL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 329
  • Fiscal Year EndDecember
  • IPO Date2017-08-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.zealandpharma.com
View More

Valuation

  • Trailing PE 10.13
  • Price/Sales (Trailing 12 Mt.) 20.68
  • Price/Book (Most Recent Quarter) 7.01
  • Enterprise Value Revenue 3.26
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$4.20
  • Next Year EPS Estimate -$3.64
  • Profit Margin -240%
  • Return on Assets -30%
  • Return on Equity -69%
  • Earnings Per Share $3.00
  • Revenue Per Share $0
  • Gross Profit 262.75 million
  • Quarterly Earnings Growth 451.3%
View More

Highlights

  • Market Capitalization 1.31 billion
  • Analyst Target Price $39.59
  • Book Value Per Share $6.32
View More

Share Statistics

  • Shares Outstanding 43.34 million
  • Shares Float 30.68 million
  • % Held by Insiders 1%
  • % Held by Institutions 4.24%
  • Shares Short 154865
  • Shares Short Prior Month 104811
  • Short Ratio 7.4
View More

Technicals

  • Beta 0.94
  • 52 Week High $44.42
  • 52 Week Low $26.82
  • 50 Day Moving Average 32.58
  • 200 Day Moving Average 36.11
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Zealand Pharma A/S (ZEAL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Zealand Pharma A/S (ZEAL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$1.56-$0.97-61.54%
2020-09-302020-11-12$N/A-$0.91-$0.89-3.1%
2020-06-302020-08-13$N/A-$0.25-$0.4240.61%
2020-03-312020-05-14$12.42 million-$0.72-$0.66-8.89%
2019-12-312020-03-11$11.49 million-$0.81-$0.37-121.17%
2019-09-302019-11-14$9.92 million-$0.51-$0.51-0.16%
2019-06-302019-08-15$19.92 million-$0.65-$0.674.17%
2019-03-312019-05-16$N/A-$0.62-$0.60-2.33%
2018-12-312019-03-07$7298.89-$0.59-$0.7318.41%
2018-09-302018-11-15$N/A$4.56$5.19-12.05%
2018-06-302018-08-16$2.36 million-$0.66
2018-03-312018-05-16$1.61 million-$0.49
2017-12-312018-03-07$2.17 million-$0.61-$0.50-22.38%
2017-09-302017-11-08$6.66 million-$0.23-$0.3736.87%
2017-06-302017-08-24$2.27 million-$0.55

Zealand Pharma A/S (ZEAL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 164.65 million 180.69 million
Income Before Tax N/A N/A N/A -180.45 million -194.86 million
Selling General Administrative N/A N/A N/A 25.08 million 16.67 million
Gross Profit N/A N/A N/A 12.42 million 11.49 million
Ebit N/A N/A N/A -177.2 million -198.74 million
Operating Income N/A N/A N/A -177.2 million -185.81 million
Income Tax Expense 8.76 million 621000 -1.38 million N/A -177397.57
Total Revenue N/A N/A N/A 12.42 million 11.49 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -689.13
Net Income From Continuing Operations N/A N/A N/A -179.52 million -193.68 million
Net Income Applicable to Common Shares -380.55 million -228.57 million -58.18 million N/A -29.07 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -18.7 million -3.21 million -18.6 million
Change to Liabilities N/A N/A N/A 2.56 million N/A
Total Cash Flow from Investing Activities -14.37 million -167.73 million N/A -482065.14 -2.72 million
Net Borrowings 5.04 million -12.42 million N/A -637700.74 -60293.73
Total Cash Flow from Financial Activities N/A N/A 144.63 million 18.47 million 553.49 million
Change to Operating Activities 129.69 million -54.78 million N/A 4.22 million -2.1 million
Change in Cash N/A N/A -86.45 million -152.96 million 384.34 million
Total Cash from Operating Activities -98.11 million -101.14 million -212.38 million -25.25 million -21.98 million
Depreciation N/A N/A N/A 1041.84 907.32
Other Cash Flow from Investing Activities 728000 -4.31 million N/A 860573.32 -652865.78
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A -1603.57 -1396.52
Other Cash Flow from Financing Activities -729000 -41.96 million N/A -2.17 million -2.11 million
Change to Net Income -18.62 million 5.57 million N/A -1.85 million -3.35 million
Capital Expenditures N/A N/A 3.7 million 8.95 million 14.13 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 346.2 million 356.84 million
Total Stockholder Equity N/A N/A N/A 1.22 billion 1.24 billion
Other Current Liabilities 234.37 million 189.29 million N/A N/A 6610.6
Total Assets N/A N/A N/A 1.56 billion 1.6 billion
Common Stock 39.8 million 39.78 million 39.73 million N/A 5.41 million
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -2.29 billion -1.91 billion -1.68 billion -1.62 billion -1.44 billion
Other Liabilities 61.33 million 56.35 million 61.31 million N/A 12.55 million
Other Assets 39.41 million 20.9 million 20.5 million N/A 1.35 million
Cash N/A N/A N/A 999.71 million 1.08 billion
Total Current Liabilities 355.26 million 293.5 million N/A 187.65 million 195.13 million
Other Stockholder Equity 8.98 million 2.41 million -328000 N/A N/A
Property, Plant & Equipment 213.04 million 226.28 million 230.91 million N/A 18.81 million
Total Current Assets 1.42 billion 1.7 billion N/A 1.37 billion 1.43 billion
Long Term Investments N/A N/A N/A 36.45 million 35.63 million
Net Tangible Assets 1.17 billion 1.51 billion 1.76 billion N/A 186.13 million
Short Term Investments N/A N/A N/A 290.94 million 299.45 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory 65.04 million 75.16 million N/A N/A N/A
Accounts Payable 70.38 million 61.7 million N/A 41.74 million 57.53 million

Zealand Pharma A/S (ZEAL) Chart:

Zealand Pharma A/S (ZEAL) News:

Below you will find a list of latest news for Zealand Pharma A/S (ZEAL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Zealand Pharma A/S (ZEAL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Zealand Pharma A/S (ZEAL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920078682/0001104659-20-078682-index.htm
2019-09-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1674988/000000000019014017/0000000000-19-014017-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1674988/000090221920000257/0000902219-20-000257-index.htm
2020-03-1320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1674988/000104746920001482/0001047469-20-001482-index.htm
2019-09-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919049859/0001104659-19-049859-index.htm
2019-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919050190/0001104659-19-050190-index.htm
2019-09-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1674988/000110465919050343/0001104659-19-050343-index.htm
2019-09-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1674988/000110465919050574/0001104659-19-050574-index.htm
2019-09-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919051194/0001104659-19-051194-index.htm
2019-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919052016/0001104659-19-052016-index.htm
2019-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919055677/0001104659-19-055677-index.htm
2019-11-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919064697/0001104659-19-064697-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919067209/0001104659-19-067209-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919068535/0001104659-19-068535-index.htm
2019-12-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919068748/0001104659-19-068748-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919070802/0001104659-19-070802-index.htm
2019-12-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919071754/0001104659-19-071754-index.htm
2019-12-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919071755/0001104659-19-071755-index.htm
2019-12-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919071840/0001104659-19-071840-index.htm
2019-12-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919073076/0001104659-19-073076-index.htm
2019-12-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919073081/0001104659-19-073081-index.htm
2019-12-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465919077178/0001104659-19-077178-index.htm
2020-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920013175/0001104659-20-013175-index.htm
2020-02-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920016274/0001104659-20-016274-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1674988/000110465920021862/0001104659-20-021862-index.htm
2020-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920032785/0001104659-20-032785-index.htm
2020-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920032787/0001104659-20-032787-index.htm
2020-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920033195/0001104659-20-033195-index.htm
2020-03-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920037288/0001104659-20-037288-index.htm
2020-03-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920037290/0001104659-20-037290-index.htm
2020-03-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920037292/0001104659-20-037292-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920039089/0001104659-20-039089-index.htm
2020-03-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920040176/0001104659-20-040176-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920042381/0001104659-20-042381-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920042382/0001104659-20-042382-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920042384/0001104659-20-042384-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920042399/0001104659-20-042399-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920042400/0001104659-20-042400-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920043932/0001104659-20-043932-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920043947/0001104659-20-043947-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920044725/0001104659-20-044725-index.htm
2020-04-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920049313/0001104659-20-049313-index.htm
2020-05-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920054918/0001104659-20-054918-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920062754/0001104659-20-062754-index.htm
2020-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920065421/0001104659-20-065421-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920065833/0001104659-20-065833-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920066353/0001104659-20-066353-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920067754/0001104659-20-067754-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920067756/0001104659-20-067756-index.htm
2020-06-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920073440/0001104659-20-073440-index.htm
2020-06-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920073526/0001104659-20-073526-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920074545/0001104659-20-074545-index.htm
2020-06-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920075630/0001104659-20-075630-index.htm
2020-06-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920076717/0001104659-20-076717-index.htm
2020-06-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920076724/0001104659-20-076724-index.htm
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920078682/0001104659-20-078682-index.htm
2020-07-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920081037/0001104659-20-081037-index.htm
2020-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920094974/0001104659-20-094974-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920098189/0001104659-20-098189-index.htm
2020-09-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920101582/0001104659-20-101582-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920102756/0001104659-20-102756-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920105436/0001104659-20-105436-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920105440/0001104659-20-105440-index.htm
2020-09-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920107232/0001104659-20-107232-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1674988/000110465920110117/0001104659-20-110117-index.htm
2020-06-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1674988/999999999720003737/9999999997-20-003737-index.htm